

### **POSTER PRESENTATION**

**Open Access** 

# Timing of continuous renal replacement therapies in acute kidney injury patients after cardiac surgery

P Cardenas Campos<sup>\*</sup>, J Sabater Riera, G Moreno Gonzalez, VF Corral Velez, JM Vazquez Reveron, RS Contreras Medina, ND Toapanta Gaibor, VD Gumucio Sanguino, XL Perez Fernandez

From ESICM LIVES 2015 Berlin, Germany. 3-7 October 2015

#### Introduction

Cardiac surgery-associated acute kidney injury (CSA-AKI) is a common postoperative complication, despite advances in surgical techniques and intensive care, mortality and morbidity associated with acute renal failure have not markedly changed in the last decade. Depending on the definition used, the incidence of CSA-AKI is reported to range from 1 to 30%. CSA-AKI requiring continuous renal replacement therapy (CRRT) occurs in 1.2-3.0% of cardiac surgery cohorts and is independently associated with mortality.

#### **Objectives**

We studied mortality differences between CRRT and nonCRRT patients. We studied Timing effect (Early vs Late CRRT initiation respect to ICU admission) using non-CRRT as control group.

#### **Methods**

We performed an observational prospective cohort study of 2100 patients undergoing different types of cardiac surgery, from 2006 to 2011 in a tertiary university hospital. Of these, 87 patients developed AKIN 2-3 stage within the first 24h of immediate postsurgical ICU admission, whereas 30 patients received CRRT during their ICU stay. All those patients with CKD 4-5 were excluded. Severity of AKI was defined by AKIN score (urine output (UO) and serum creatinine). We classified patients in early group ( < 48 hours) and late group (>48 hours) based on time from ICU admission to CRRT.

#### **Results**

Baseline patients characteristics were: Mean age (years)  $65 \pm 10$ ; APACHE II  $20 \pm 8$ ; SOFA  $10 \pm 3$ ; UO (ml) 6h before CRRT  $161 \pm 225$ ; Creatinine at CRRT initiation (umol/L)  $298,20 \pm 98$ . Mortality at 90 days in patients with AKIN 2-3 the first 24h of ICU admission was 37,9%. The mortality in patients with AKIN 2-3 that required CRRT was 63,3%, compared with 24,6% in patients that did not require CRRT. Timing analysis was performed (Early vs Late) using non CRRT as control group: Mean age in years  $(60 \pm 8 \text{ vs } 70 \pm 7) \text{ vs } 66 \pm 10$ ; SOFA  $(11 \pm 3 \text{ vs } 11 \pm 3) \text{ vs } 10 \pm 3$ ; APACHE  $(22 \pm 6 \text{ vs } 23 \pm 7) \text{ vs } 19 \pm 8$ ; Creatinine at ICU admission (umol/L)  $(55 \pm 14 \text{ vs } 66 \pm 17) \text{ vs } 59 \pm 8$ ; UO 24h at ICU admission (ml/k/h)  $(0,3 \pm 0,2 \text{ vs } 0,7 \pm 0,5) \text{ vs } 0,8 \pm 0,4$ ; Urine output 6h previous to CRRT  $(0,2 \pm 0,2 \text{ vs } 0,5 \pm 0,6)^*$ . \*p < 0,05.

#### **Conclusions**

Higher mortality in those AKIN 2-3 whom needed CRRT vs non-CRRT (63.3% vs 24.6%). Timing analysis revealed no survival differences between those patients who were early initiated on CRRT ( < 48 h respect to ICU admission) and those who were initiated later (60.0% VS 66.7%). Urine output 6h previous to CRRT was significative higher in the late group respect to the early group (0.54 ml/kg/h vs 0.18 ml/gh/h) introducing some concerns about CRRT indication on this Late group. CRRT initiation in advanced AKIN patients (AKIN 2-3) who still present preserved UO > 0.5 ml/k/h should be discouraged, these patients present higher mortality compared to non-CRRT patients.

Hospital Universitari de Bellvitge, Barcelona, Spain



Published: 1 October 2015

#### doi:10.1186/2197-425X-3-S1-A261

Cite this article as: Cardenas Campos *et al.*: Timing of continuous renal replacement therapies in acute kidney injury patients after cardiac surgery. *Intensive Care Medicine Experimental* 2015 **3**(Suppl 1):A261.

## Submit your manuscript to a SpringerOpen journal and benefit from:

- ► Convenient online submission
- ► Rigorous peer review
- ▶ Immediate publication on acceptance
- ► Open access: articles freely available online
- ► High visibility within the field
- ► Retaining the copyright to your article

Submit your next manuscript at ► springeropen.com